CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Oral Irondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02979249
NCT02979249N/ACompleted

Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias

Icahn School of Medicine at Mount Sinai·interventional·Posted Dec 1, 2016·Updated Sep 11, 2020

In Brief

A clinical study evaluating Oral Iron for Erythropoietic Protoporphyria and 3 related conditions. Completed, enrolled 16 participants across 6 sites.

Detailed Summary

In the medical literature there are conflicting reports on whether iron improves symptoms in patients with EPP and XLP. Giving iron to people who are iron deficient is thought to improve EPP symptoms. However, this has never been systematically tested. Therefore, the purpose of this study is to determine the effect of oral iron for EPP and XLP patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 1, 2016
Enrollment StartDec 1, 2016
Primary CompletionJul 19, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.6 years ago

Interventions

Oral Irondrug

for one year